Skip to main content
Springer Nature Link
Log in

Pharmacotherapy of Social Anxiety Disorder

  • Chapter
  • First Online:
Behavioral Neurobiology of Anxiety and Its Treatment

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 2))

Abstract

A range of medications have been shown effective for the treatment of social anxiety disorder. The largest trials to date have been with various selective serotonin reuptake inhibitors (SSRIs). Several of these agents have been registered for the treatment of social anxiety disorder with agencies such as the FDA or EMEA, meta-analyses confirm their efficacy and safety, and expert consensus guidelines have often recommended them as a first-line pharmacotherapy of choice. Despite such advances, there are many unanswered questions in the pharmacotherapy of social anxiety disorder, including the optimal pharmacotherapy of patients refractory to first-line intervention, and the optimal sequencing of pharmacotherapy and psychotherapy. Translational research has already had an impact on concepts of treatment, and may ultimately lead to novel interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Aarre TF (2003) Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord J Psychiatry 57:313–315

    Article  PubMed  Google Scholar 

  • Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G (2004) Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 19:387–396

    Article  PubMed  CAS  Google Scholar 

  • Asakura S, Tajima O, Koyama T (2007) Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 10:263–274

    Article  PubMed  CAS  Google Scholar 

  • Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU, British Association for Psychopharmacology (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567–596

    Article  PubMed  CAS  Google Scholar 

  • Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Bobes J, Beidel DC, Ono Y, Westenberg HG (1998) Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59:54–60

    PubMed  Google Scholar 

  • Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ (2008) World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 9:248–312

    Article  PubMed  Google Scholar 

  • Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR (2002) Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 16:365–368

    Article  PubMed  CAS  Google Scholar 

  • Bieck PR, Antonin KH (1989) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm Suppl 1989:21–31

    Google Scholar 

  • Blanco C, Raza MS, Schneier FR, Liebowitz MR (2003) The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol 6:427–442

    Article  PubMed  CAS  Google Scholar 

  • Clark DB, Agras WS (1991) The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 148:598–605

    PubMed  CAS  Google Scholar 

  • Compton SN, Grant PJ, Chrisman AK, Gammon PJ, Brown VL, March JS (2001) Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 40:564–571

    Article  PubMed  CAS  Google Scholar 

  • Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH (1993) Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 13:423–428

    Article  PubMed  CAS  Google Scholar 

  • Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM (2004) Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social anxiety disorder. Arch Gen Psychiatry 61:1005–1013

    Article  PubMed  CAS  Google Scholar 

  • Davis M, Ressler K, Rothbaum BO, Richardson R (2006) Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 60:369–375

    Article  PubMed  CAS  Google Scholar 

  • Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U (1995) Social anxiety disorder: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand 92:351–358

    Article  PubMed  CAS  Google Scholar 

  • Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M (2002) Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42:229–236

    Article  PubMed  CAS  Google Scholar 

  • Foa EB, Franklin ME, Moser J (2002) Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry 52:987–997

    Article  PubMed  Google Scholar 

  • Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, Fredrikson M (2002) Common changes in cerebral blood flow in patients with social anxiety disorder treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry 59:425–433

    Article  PubMed  Google Scholar 

  • Furmark T, Tillfors M, Garpenstrand H, Marteinsdottir I, Langstrom B, Oreland L, Fredrikson M (2004) Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social anxiety disorder. Neurosci Lett 362:189–192

    Article  PubMed  CAS  Google Scholar 

  • Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ (1991) Cognitive-behavioral and pharmacological treatments of social anxiety disorder. A controlled study. Arch Gen Psychiatry 48:938–945

    Article  PubMed  CAS  Google Scholar 

  • Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR (2008) A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 63:544–549

    Article  PubMed  CAS  Google Scholar 

  • Hartley LR, Ungapen S, Davie I, Spencer DJ (1983) The effect of beta adrenergic blocking drugs on speakers’ performance and memory. Br J Psychiatry 142:512–517

    Article  PubMed  CAS  Google Scholar 

  • Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW (2006) Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63:298–304

    Article  PubMed  CAS  Google Scholar 

  • Ipser JC, Kariuki CM, Stein DJ (2008) Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 8:235–257

    Article  PubMed  CAS  Google Scholar 

  • Isolan L, Pheula G, Salum GA Jr, Oswald S, Rohde LA, Manfro GG (2007) An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol 17:751–760

    Article  PubMed  Google Scholar 

  • James IM, Burgoyne W, Savage IT (1983) Effect of pindolol on stress-related disturbances of musical performance: preliminary communication. J R Soc Med 76:194–196

    PubMed  CAS  Google Scholar 

  • Kasper S, Stein DJ, Loft H, Nil R (2005) Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222–226

    Article  PubMed  Google Scholar 

  • Katschnig H (1997) The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social anxiety disorder. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 247:71–80

    Article  Google Scholar 

  • Kelly D (1973) Phenelzine in phobic states. Proc R Soc Med 66:949–950

    PubMed  CAS  Google Scholar 

  • Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ (2002) Fluoxetine in social anxiety disorder: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 22:257–262

    Article  PubMed  CAS  Google Scholar 

  • Lader M, Stender K, Burger V, Nil R (2004) Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19:241–248

    Article  PubMed  CAS  Google Scholar 

  • Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L (2004) Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 65:222–229

    Article  PubMed  CAS  Google Scholar 

  • Liebowitz MR, Gorman JM, Fyer AJ, Klein DF (1985) Social anxiety disorder. Review of a neglected anxiety disorder. Arch Gen Psychiatry 42:729–736

    Article  PubMed  CAS  Google Scholar 

  • Liebowitz MR, Schneier F, Campeas R, Gorman J, Fyer A, Hollander E, Hatterer J, Papp L (1990) Phenelzine and atenolol in social anxiety disorder. Psychopharmacol Bull 26:123–125

    PubMed  CAS  Google Scholar 

  • Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R (1992) Phenelzine vs atenolol in social anxiety disorder. A placebo-controlled comparison. Arch Gen Psychiatry 49:290–300

    PubMed  CAS  Google Scholar 

  • Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, Goetz D, Juster HR, Lin SH, Bruch MA, Marshall RD, Klein DF (1999) Cognitive-behavioral group therapy versus phenelzine in social anxiety disorder: long-term outcome. Depress Anxiety 10:89–98

    Article  PubMed  CAS  Google Scholar 

  • Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD (2002) A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63:66–74

    Article  PubMed  CAS  Google Scholar 

  • Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM (2003) Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64:785–792

    Article  PubMed  CAS  Google Scholar 

  • Liebowitz MR, Gelenberg AJ, Munjack D (2005a) Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 62:190–198

    Article  PubMed  CAS  Google Scholar 

  • Liebowitz MR, Mangano RM, Bradwejn J, Asnis G (2005b) A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66:238–247

    Article  PubMed  CAS  Google Scholar 

  • Lott M, Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Katz RJ, Schaettle SC (1997) Brofaromine for social anxiety disorder: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 17:255–260

    Article  PubMed  CAS  Google Scholar 

  • Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP (2005) A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66:1270–1278

    Article  PubMed  CAS  Google Scholar 

  • Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa GF, Leiberich PK, Rother N, Bachler E, Fartacek R, Kaplan P, Tritt K, Mitterlehner F, Anvar J, Rother WK, Loew TH, Egger C (2005) Mirtazapine treatment of social anxiety disorder in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 25:580–583

    Article  PubMed  CAS  Google Scholar 

  • Noyes R Jr, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, Bell J, Cain JW, Curlik SM, Kent TA, Lydiard RB, Mallinger AG, Pollack MH, Rapaport M, Rasmussen SA, Hedges D, Schweizer E, Uhlenhuth EH (1997) Moclobemide in social anxiety disorder: a controlled dose-response trial. J Clin Psychopharmacol 17:247–254

    Article  PubMed  CAS  Google Scholar 

  • Pallanti S, Quercioli L (2006) Resistant social anxiety disorder response to Escitalopram. Clin Pract Epidemol Ment Health 2:35

    Article  Google Scholar 

  • Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM (1999) Treatment of social anxiety disorder with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19:341–348

    Article  PubMed  CAS  Google Scholar 

  • Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney CA, Werth JL (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 24:141–149

    Article  PubMed  CAS  Google Scholar 

  • Prasko J, Dockery C, Horacek J, Houbova P, Kosova J, Klaschka J, Paskova B, Praskova H, Seifertova D, Zalesky R, Hoschl C (2006) Moclobemide and cognitive behavioral therapy in the treatment of social anxiety disorder. A six-month controlled study and 24 months follow up. Neuro Endocrinol Lett 27:473–481

    PubMed  CAS  Google Scholar 

  • Rodebaugh TL, Holaway RM, Heimberg RG (2004) The treatment of social anxiety disorder. Clin Psychol Rev 24:883–908

    Article  PubMed  Google Scholar 

  • Schneier FR, Saoud JB, Campeas R, Fallon BA, Hollander E, Coplan J, Liebowitz MR (1993) Buspirone in social anxiety disorder. J Clin Psychopharmacol 13:251–256

    PubMed  CAS  Google Scholar 

  • Seedat S, Stein MB (2004) Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 65:244–248

    PubMed  CAS  Google Scholar 

  • Segool NK, Carlson JS (2008) Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety. Depress Anxiety 25:620–631

    Article  PubMed  Google Scholar 

  • Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH (2006) An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67:381–385

    Article  PubMed  CAS  Google Scholar 

  • Stein MB, Stein DJ (2008) Social anxiety disorder. Lancet 371:1115–1125

    Article  PubMed  Google Scholar 

  • Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B (1999) Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156:756–760

    PubMed  CAS  Google Scholar 

  • Stein MB, Sareen J, Hami S, Chao J (2001) Pindolol potentiation of paroxetine for generalized social anxiety disorder: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 158:1725–1727

    Article  PubMed  CAS  Google Scholar 

  • Stein DJ, Cameron A, Amrein R, Montgomery SA (2002a) Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 17:161–170

    Article  PubMed  CAS  Google Scholar 

  • Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B (2002b) Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 63:152–155

    Article  PubMed  CAS  Google Scholar 

  • Stein DJ, Versiani M, Hair T, Kumar R (2002c) Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 59:1111–1118

    Article  PubMed  CAS  Google Scholar 

  • Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM (2003) Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 6:317–323

    Article  PubMed  CAS  Google Scholar 

  • Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM (2005) Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 177:280–288

    Article  CAS  Google Scholar 

  • Stein MB, Seedat S, Gelernter J (2006) Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl) 187:68–72

    Article  CAS  Google Scholar 

  • Swinson RP, Antony MM, Bleau PB, Chokka P, Craven M, Fallu A et al (2006) Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry 51(S2):1–92

    Google Scholar 

  • Tyrer P, Candy J, Kelly D (2003) Phenelzine in phobic anxiety: a controlled trial. Psychol Med 3:120–124

    Article  Google Scholar 

  • Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JR (2007) Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 31:1464–1469

    Article  PubMed  CAS  Google Scholar 

  • Van Ameringen M, Mancini C, Wilson C (1996) Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social anxiety disorder. J Affect Disord 39:115–121

    Article  PubMed  Google Scholar 

  • Van Ameringen M, Mancini C, Oakman J, Walker J, Kjernisted K, Chokka P, Johnston D, Bennett M, Patterson B (2007) Nefazodone in the treatment of generalized social anxiety disorder: a randomized, placebo-controlled trial. J Clin Psychiatry 68:288–295

    Article  PubMed  Google Scholar 

  • Van Vliet IM, den Boer JA, Westenberg HG (1994) Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 115:128–134

    Article  Google Scholar 

  • Van Vliet IM, den Boer JA, Westenberg HG, Pian KL (1997) Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 58:164–168

    Article  PubMed  Google Scholar 

  • Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R (1992) Pharmacotherapy of social anxiety disorder. A controlled study with moclobemide and phenelzine. Br J Psychiatry 161:353–360

    Article  PubMed  CAS  Google Scholar 

  • Versiani M, Nardi AE, Figueira I, Mendlowicz M, Marques C (1997) Double-blind placebo controlled trial with bromazepam in social anxiety disorder. J Bras Psiquiatr 3:167–171

    Google Scholar 

  • Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A (2004) A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61:1153–1162

    Article  PubMed  CAS  Google Scholar 

  • Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, Johnston DC, Lavallie YJ, Nandy S, Pecknold JC, Hadrava V, Lane RM (2000) Prevention of relapse in generalized social anxiety disorder: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 20:636–644

    Article  PubMed  CAS  Google Scholar 

  • Walkup JT, Labellarte MJ, Riddle MA et al (2001) Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. N Engl J Med 344:1279–1285

    Article  CAS  Google Scholar 

  • Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC (2008) Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 359:2753–2766

    Article  PubMed  CAS  Google Scholar 

  • Warwick JM, Carey P, van der Linden G, Prinsloo C, Niehaus D, Seedat S, Dupont P, Stein DJ (2006) A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder. Metab Brain Dis 21:241–252

    Article  PubMed  CAS  Google Scholar 

  • Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM (2004) A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:49–55

    Article  PubMed  CAS  Google Scholar 

  • Zhang W, Connor KM, Davidson JR (2005) Levetiracetam in social anxiety disorder: a placebo controlled pilot study. J Psychopharmacol 19:551–553

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Mental Health, University of Cape Town, J-Block, Groote Schuur Hospital, Anzio Rd, Observatory, 7925, Cape Town, South Africa

    Keith A. Ganasen & Dan J. Stein

Authors
  1. Keith A. Ganasen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan J. Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keith A. Ganasen .

Editor information

Editors and Affiliations

  1. Dept. Psychiatry, University of California, San Diego, Gilman Drive 9500, La Jolla, 92093-0985, USA

    Murray B. Stein

  2. Research & Development, CNS - Affective Spectrum, Johnson & Johnson Pharmaceutical, Turnhoutseweg 30, Beerse, 2340, Belgium

    Thomas Steckler

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ganasen, K.A., Stein, D.J. (2009). Pharmacotherapy of Social Anxiety Disorder. In: Stein, M., Steckler, T. (eds) Behavioral Neurobiology of Anxiety and Its Treatment. Current Topics in Behavioral Neurosciences, vol 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2009_1

Download citation

Publish with us

Policies and ethics